Altimmune’s Pemvidutide Garners Mixed Reviews Following Phase II Obesity Data
Stock Down By 55%
The US firm’s GLP-1/glucagon receptor agonist improved weight loss in a Phase II interim analysis, but concerns about drug safety and discontinuation have left investors cynical, even as analysts remain cautiously upbeat.
